During the corresponding time, Lexicon Pharmaceuticals Inc saw a revenue deteriorated by -97.6 % year on year, sequentially revenue fell by -96.72 %. While revenue at the Lexicon Pharmaceuticals Inc 's corporate clients
Lexicon Pharmaceuticals Inc's Comment on Sales, Marketing and Customers
The company operates in markets related to treatments for hypertrophic cardiomyopathy, type 1 diabetes, diabetic peripheral neuropathic pain (DPNP), weight loss, and heart failure. Its customer base includes physicians and other healthcare providers who prescribe these treatments. The company competes with generic beta blockers, selective SGLT2 inhibitors, calcium channel blockers, cardiac myosin inhibitors, established insulin therapies, duloxetine, pregabalin, suzetrigine, gabapentin, GLP-1 analogs, sacubitril/valsartan, vericiguat, and older generic medications such as beta-blockers and diuretics. Competitors include Bristol Myers Squibb, Cytokinetics, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Pfizer, Vertex, Novo Nordisk, Novartis, and Merck. Customers and markets identified in company filings include AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Eli Lilly, Merck, Novartis, Novo Nordisk, Pfizer, and Vertex.
Lexicon s Zynquista Setback: Navigating the Regulatory Maze In the complex maze of pharmaceutical regulations and approvals, Lexicon Pharmaceuticals recently encountered a significant hurdle. The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) concerning Zynquista, their innovative sotagliflozin drug candidate, which was anticipated following preliminary disclosures by the company. This development underscores the intricate process of drug approval and the strategic foresight required by pharmaceutical companies to navigate it.The FDA s decision to issue a CRL essentially a formal communication indicating that the agency cannot approve the drug in its current form was not ent...
Lexicon Pharmaceuticals Inc. a biopharmaceutical company focused on developing innovative therapies for a range of diseases, recently announced the completion of enrollment in the Phase 2B PROGRESS study of LX9211, which is aimed at treating diabetic peripheral neuropathic pain (DPNP). This milestone marks significant progress in LX9211 s developmental timeline, emphasizing the potential impact this treatment could have on the lives of patients suffering from DPNP. Encouraging Progress in the Clinical Trial The completion of enrollment in the PROGRESS study is noteworthy not only because it meets the company s developmental s but also because it surpasses initial expectations. The trial reported an enrollmen...
The burgeoning fields of obesity and cardiometabolic disease research have seen significant advancements recently, particularly in the development of novel therapeutic agents. The investigational compound LX9851 represents a promising new approach to obesity management, while the established molecule sotagliflozin is carving a path as a multi-faceted treatment for diabetes and heart failure. This article synthesizes key findings from recent studies demonstrating the clinical efficacy and potential implications of these compounds. LX9851: A New Frontier in Obesity TreatmentLexicon Pharmaceuticals is on track to submit an Investigational New Drug (IND) application in 2025 for LX9851, heralded as a first-in-cl...
Exploring the Promise of Sotagliflozin: A Deep Dive into Efficacy and Safety for Type 1 Diabetes Patients with Chronic Kidney Disease In the landscape of diabetes management, ongoing research continues to shed light on potential therapies that enhance both efficacy and safety for patients with complex comorbidities. One such therapy that has garnered attention is Sotagliflozin, a dual inhibitor targeting both the sodium-glucose co-transporter 1 (SGLT1) and sodium-glucose co-transporter 2 (SGLT2). This treatment approaches diabetes management, particularly in patients with Type 1 Diabetes (T1D) who are facing the added challenge of chronic kidney disease (CKD). At the 2024 Annual Conference of the Association...
Lexicon Pharmaceuticals Resubmits NDA for Sotagliflozin Amid Compelling New Data Lexicon Pharmaceuticals has resubmitted its New Drug Application (NDA) for sotagliflozin, aiming to receive approval for its use as an adjunct to insulin therapy in the management of Type 1 Diabetes (T1D) and chronic kidney disease. The submission coincides with the company s latest research findings presented at the 84th Scientific Sessions of the American Diabetes Association (ADA), accentuating sotagliflozin s efficacy in reducing the risk of heart failure events in patients with preserved ejection fraction and its potential to alleviate diabetic peripheral neuropathic pain (DPNP). BackgroundOn June 14, 2024, Lexicon Pharmac...
The search for novel therapeutic approaches to manage heart failure has led to significant advancements in recent years. The emerging class of sodium-glucose cotransporter 2 (SGLT2) inhibitors has revolutionized the treatment landscape, demonstrating substantial benefits in cardiovascular outcomes. Building on this foundation, a new post-hoc analysis of pooled Phase 3 data unveils promising evidence highlighting the potential of INPEFA (Sotagliflozin) as a dual oral inhibitor of both SGLT2 and SGLT1. This analysis offers a deeper understanding of INPEFA s efficacy in reducing heart failure events, particularly in patients with preserved ejection fraction.Differentiating INPEFA as a Dual Oral Inhibitor:The an...
Lexicon Pharmaceuticals has recently announced the enrollment of the first patient in the Phase 2b PROGRESS study for LX9211—a promising AAK1 inhibitor—for the treatment of Diabetic Peripheral Neuropathic Pain (DPNP). This milestone signifies the initiation of the late-stage development program for LX9211, representing a crucial step towards addressing the high unmet medical need for non-opioid drug therapy in neuropathic pain, an area that has seen limited advancements in the past two decades.
Lexicon Pharmaceuticals, a trusted name in the pharmaceutical industry, has set a new course in the realm of neuropathic pain management with the commencement of the PROGRESS study. This study f...
Lexicon Pharmaceuticals Inc’s Comment on Sales, Marketing and Customers
The company operates in markets related to treatments for hypertrophic cardiomyopathy, type 1 diabetes, diabetic peripheral neuropathic pain (DPNP), weight loss, and heart failure. Its customer base includes physicians and other healthcare providers who prescribe these treatments. The company competes with generic beta blockers, selective SGLT2 inhibitors, calcium channel blockers, cardiac myosin inhibitors, established insulin therapies, duloxetine, pregabalin, suzetrigine, gabapentin, GLP-1 analogs, sacubitril/valsartan, vericiguat, and older generic medications such as beta-blockers and diuretics. Competitors include Bristol Myers Squibb, Cytokinetics, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Pfizer, Vertex, Novo Nordisk, Novartis, and Merck. Customers and markets identified in company filings include AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Eli Lilly, Merck, Novartis, Novo Nordisk, Pfizer, and Vertex.
Sources:
Lexicon Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Lexicon Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Lexicon Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
255.78 %